The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab (Tecentriq) as an additional, or adjuvant, treatment after surgery and chemotherapy for some patients with non-small cell lung cancer (NSCLC). Atezolizumab (Tecentriq) is approved as an additional treatment for some patients with stage II to IIIA (pictured) non-small cell lung cancer. The approval marks the […]
Read more of this post
No comments:
Post a Comment